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It has been widely hypothesized that both diet and the microbiome play a role in the regulation of 
attention-deficit/hyperactivity disorder (ADHD) behaviour. However, there has been very limited 
scientific investigation into the potential biological connection. We performed a 10-week pilot study 
investigating the effects of a broad spectrum micronutrient administration on faecal microbiome 
content, using 16S rRNA gene sequencing. The study consisted of 17 children (seven in the placebo 
and ten in the treatment group) between the ages of seven and 12 years, who were diagnosed with 
ADHD. We found that micronutrient treatment did not drive large-scale changes in composition or 
structure of the microbiome. However, observed OTUs significantly increased in the treatment group, 
and showed no mean change in the placebo group. The differential abundance and relative frequency of 
Actinobacteria significantly decreased post- micronutrient treatment, and this was largely attributed 
to species from the genus Bifidobacterium. This was compensated by an increase in the relative 
frequency of species from the genus Collinsella. Further research is required to establish the role that 
Bifidobacterium contribute towards neuropsychiatric disorders; however, these findings suggest that 
micronutrient administration could be used as a safe, therapeutic method to modulate Bifidobacterium 
abundance, which could have potential implications for modulating and regulating ADHD behaviour. 
Our pilot study provides an initial observation into this area of research, and highlights an interesting 
avenue for further investigation in a larger cohort. Furthermore, these novel results provide a basis for 
future research on the biological connection between ADHD, diet and the microbiome.
Understanding the molecular interactions between nutrition, and mental health and disease is an important 
challenge for medical biology1. A growing body of evidence indicates that nutritional components impact on both 
physical and mental health, suggesting that specific dietary manipulations may be a useful form of treatment for 
some diseases2–4. Dietary supplementation with a broad spectrum of micronutrients (vitamins, minerals, amino 
acids) is one such treatment option that is gaining support in the scientific literature, with demonstrated benefits 
in modulating attention-deficit/hyperactivity disorder (ADHD), mood, anxiety, stress, aggression and symptoms 
associated with autism5–8. However, there is little scientific research into the biochemical effects of dietary supple-
ments or investigation into the potential biological pathways through which they may act9.
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It has been hypothesized that alterations in the human gut microbiota by micronutrients10–15, may have a 
biochemical effect via the vagus and spinal nerves16, which enable bidirectional communication between the gut 
and the brain, referred to as the gut-brain axis17,18. Through this pathway, metabolites can act as modulators in 
neural, immunological and hormonal signalling, which have important implications for health and disease19–21. 
Although the exact mechanisms are not fully understood, diet is thought to be one of the most influential factors 
on the microbiome22–24.
The microbiome has been observed to play an important role in anxiety-like behaviour in animal studies22,25, 
and this has been observed in human patients with irritable bowel syndrome26,27. There is also growing evidence 
supporting a role of the human gut microbiome in the development of neuropsychiatric disorders, such as depres-
sion4,18, ADHD and autism28–30. ADHD is a developmental disorder that affects approximately 7.2% of children31, 
where pharmacological treatments can reduce symptoms, but are often unsatisfactory due to side effects, failure to 
prevent or alter long-term course and discontinuance due to patient and family preferences32. Growing evidence 
is suggesting that nutrition plays an important role in ADHD behaviour33,34, with long-term studies showing that 
early malnutrition is an important risk factor35.
We performed a pilot study investigating the potential effects of micronutrients on human faecal microbiome 
content. This study was carried out in a sample of children between the ages of seven and 12 years, diagnosed with 
attention-deficit/hyperactivity disorder (ADHD). These individuals were a subset of children who had partici-
pated in a 10 week double-blind RCT comparing a broad-spectrum micronutrient treatment with a placebo to 
investigate therapeutic effects on ADHD symptoms36. In this study, micronutrient administration was associated 
with improved overall function, reduced impairment and improved attention, emotional regulation and aggres-
sion relative to placebo36.
Methods
Randomized control trial layout. This 10-week pilot study followed a standard double-blind, randomized 
control trial (RCT) design, where participants were randomized to either placebo or control. The cohort consisted 
of 18 consenting children diagnosed with ADHD, who were a sub-cohort of participants from a larger study 
that investigated the effects of dietary micronutrient supplementation on ADHD outcomes36. Faecal microbiome 
analysis was not intended at the initialisation of this large study36, and this sub-cohort represents the later male 
recruits. There was no a priori selection of candidates for participation in the microbiome analysis (Fig. 1) and the 
randomization was not influenced.
The placebo group contained eight participants and the micronutrient group contained ten participants. One 
participant in the placebo group had taken oral antibiotics during the RCT and was subsequently excluded at the 
data analysis stage, giving a final total of 34 samples (Fig. 1). For each participant, a pre-RCT, and a post-RCT 
faecal sample was collected, and microbiome sequencing analysis was performed on DNA extracted from each 
sample, giving a total of 36 samples (Supplementary File 1).
All participants were under supervised administration of capsules, where the micronutrient group received a 
formulation containing a blend of vitamins, minerals, amino acids and antioxidants (see Supplementary Table 1 
for ingredients of both treatment and placebo capsules). Participants began by taking one capsule, three times 
each day, increasing the dose by three capsules every two days up to a target dose of 12 capsules per day: four 
taken at three different intervals. Further information regarding the dosing, randomization and blinding proce-
dures is available in Rucklidge et al.36.
statistical design. Due to the RCT layout of this study, the dataset consisted of paired samples for each indi-
vidual that had been collected pre and post-RCT. Where possible, the data were analyzed using a paired-sample 
approach to appropriately incorporate the baseline data for each individual. This ensured that the study specifi-
cally investigated changes that occurred during the trial period. Significant changes were only considered true, if 
they were specific to the micronutrient-treatment, or if the magnitude of change was in the opposite direction to 
the placebo. In addition to the below methods, repeated measures correlation was performed using the R package, 
rmcorr37, and power analysis was performed using the R package, PWR38. Correlation analysis of the abundance 
data was performed within R, using the “Pearson” correlation coefficient.
Figure 1. Study design and RCT layout. The 10-week pilot study was performed with a sub-sample of 
participants from a larger study36. Study design followed a standard double-blind, randomized control trial 
(RCT), and there was no a priori selection of candidates for participation in the microbiome analysis.
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Efficacy and safety assessments. All participants were monitored by a clinical psychologist or psychol-
ogy graduate student, under the supervision of a psychologist. This was performed at the screening visit, baseline, 
and weeks 2, 4, 6, 8 and 10 (or end of study), via face-to-face meetings or via phone contact. At each visit, the 
Children’s Global Assessment Scale (CGAS)39 and ADHD Rating Scale IV (ADHD-RS-IV) – clinician40,41 were 
completed. The CGAS was used by the clinician to assess the overall level of the children’s functioning based on 
all the information gathered since the last visit. Scoring is based on a single numerical scale from 1 to 100, where 
the higher score is indicative of better functioning. At pre and post-RCT time-points, the clinician also completed 
the ADHD-RS-IV, which contains 18 items directly linked to DSM-IV diagnostic criteria for ADHD and provides 
a total score and two subscale scores for inattention and hyperactivity/impulsivity, assessing ADHD symptoms 
based on frequency (0 ‘never or rarely’ to 3 ‘very often’). The clinician took into account observations from visits 
and formal cognitive testing, information from others, as well as parent report in determining ratings. However, 
frequency of behaviours was the main focus of the rating, considering how often the behaviours were present.
At baseline and study completion, hematological variables, biochemical variables, thyroid function, prolactin, 
fasting glucose, homocysteine, iron, zinc, vitamin D, vitamin B12, copper, blood pressure, height and weight were 
also recorded. To assess the child’s dietary patterns, including consumption of fruit, vegetables, breakfast, and fast 
foods, a brief diet intake questionnaire was performed at baseline and end of RCT with a higher score indicative 
of a healthier eating pattern (modified from Baker, et al.42). Demographic variables, including participant’s eth-
nicity and parents’ occupation were also collected at baseline.
Informed consent and ethics. Written informed consent was obtained from all of the participants’ parents 
or legal guardians and assent was obtained from the participants. The trial was prospectively registered with the 
Australia and New Zealand Clinical Trial Registry ACTRN12613000896774, on the 12/08/2013. The exploratory 
nature of the study, as well as other treatment options for ADHD, was explained to participants and their parents 
prior to enrolling. This study was approved by the University of Canterbury (New Zealand) and national institu-
tional review boards. Ethical approval for this study was approved by the Southern Health and Disability Ethics 
Committee (New Zealand), Ethics ref: 13/STH/45/AM05, and all research was performed in accordance with the 
relevant guidelines.
sample collection and storage. Fresh stool samples were collected at baseline and post RCT (10 weeks) 
using the OmnigeneGut faecal collection system (DNA Genotek, Ottawa, Canada), according to the manufac-
turer’s specifications. Using this system, homogenised samples are stable for 60 days at ambient temperature, 
however, all samples were stored at −4 °C for a maximum of 14 days, before aliquoting and storage at −80 °C.
DNA Isolation and sequencing. Total DNA was extracted from stool samples using the NucleoSpin DNA 
Stool isolation kit by Macherey-Nagel (Germany, Duren), according to the manufacturer’s recommendations for 
human stool samples. Extracted DNA was stored at −20 °C until PCR amplification and Illumina MiSeq DNA 
sequencing. PCR amplification and single-end DNA sequencing of the V3/V4 regions of the 16S rRNA gene 
was outsourced to New Zealand Genomics Limited (Dunedin, New Zealand) and performed according to their 
protocols.
Bioinformatics analysis. Demultiplexed and pre-processed sequence reads were supplied by New Zealand 
Genomics Limited and these were imported into the Quantitative Insights Into Microbial Ecology (QIIME2, ver-
sion 2017.12), python-based pipeline using CASAVA 1.8. Barcode and primer removal, quality control, amplicon 
sequence data correction, phiX filtering, and dereplication was verified using the DADA2 software package43. The 
total sequence length was truncated to 220 bp, and 13 bp of low quality data were trimmed from the start of the 
sequence. This processing was separately performed on the V3 and V4 sequence runs. Feature tables and repre-
sentative sequence files were then merged for downstream analysis, within QIIME2.
Taxonomic classification. Taxonomic classification was assigned using the GreenGenes database, specific 
for the V3/V4 16S region (version 13.8). All taxonomic classifications were implemented within QIIME2 and 
assigned using the naïve Bayesian algorithm, developed for sklearn classifier. For phylogenetic diversity analysis, 
sequences were aligned using the MAFFT44 programme plugin, and then filtered to remove highly variable posi-
tions. Reads that were unassigned at the Kingdom level were removed from the OTU table, as were OTUs that 
were observed less than 100 times (Supplementary File 2). The final taxonomic classification was made against the 
filtered feature table, which had 4474 distinct features (Supplementary File 3).
Phylogenetic analysis. Alpha and Beta diversity were calculated using the q2-diversity plugin and included 
Faith’s Phylogenetic Diversity, and weighted and unweighted Unifrac distances. The feature table was rarefied to 
a sampling depth of 273,465, which retained 50.18% (9,297,810) of sequences and all samples (34). This sam-
pling depth was selected as it was approaching the maximum depth which retained all samples for our analysis. 
Principal coordinate analysis (PCoA) was used to investigate the similarities between bacterial communities, 
based on treatment using Unweighted and Weighted Fast Unifrac methods. Pairwise distance and pairwise dif-
ferences in alpha diversity values (observed operational taxonomic units) were calculated within QIIME2, using 
the q2-longitudinal plugin.
Computing species abundance using the q2-ANCOM plugin. Species abundance was assessed using 
the QIIME2 ANCOM plugin45, consecutively at each taxonomic level to detect significant changes in abundance 
between each of the four groups (micronutrient pre-RCT, micronutrient post-RCT, placebo pre-RCT and placebo 
post-RCT). Relative frequencies at each phylogenetic level were calculated by ANCOM, from the DADA2 feature 
table for assigned sequence variant.
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Analysing paired differences in abundance using the q2-longitudinal plugin. Longitudinal 
analysis of feature data from paired samples (pre and post-RCT) was performed following the methods out-
lined by Bokulich et al.46. Briefly, relative abundance was manually calculated from the DADA2 generated 
(non-rarefied) feature table, filtered to contain Actinobacteria, and consecutively collapsed at each phylogenetic 
level (Supplementary File 4 and 5). The pairwise difference between baseline and post-RCT samples for each phy-
logenetic level was then compared for the micronutrient and placebo groups. This method measures within group 
pairwise difference using Wilcoxon signed-rank tests, and pairwise group comparison tests using Kruskal Wallis.
Functional predictions. Functional predictions of metagenomics profiles were computed using two com-
mon approaches. The first approach involved analysis with the R package Tax4Fun47, and the second approach 
involved analysis with the package, Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States (PICRUSt)48, via the Galaxy platform49. For analysis with Tax4Fun, a QIIME2 closed reference feature table 
was generated using the QIIME2 vsearch plugin at 97% similarity to the SILVA50,51 database release version 132. 
For analysis using PICRUSt, the feature table was generated at 97% similarity to the Green Genes database version 
13.5.
Change in the abundance of metagenomic pathway profiles generated by each approach was then calculated 
by subtracting the baseline measurement from the post-RCT measurement, for each individual. Differentially 
abundant pathways that correlated with treatment were identified using a linear regression model within the 
Limma package52 that accounted for treatment, age, and ethnicity.
Results
participants. Participants were males who ranged from seven to 12 years (Table 1) and consisted of 13 New 
Zealand Europeans and four New Zealand Māori participants. The groups were well matched and there were no 
group differences at baseline in severity of ADHD behaviours, socio-economic status, body mass index, dietary 
patterns, or presence of other comorbid disorders. There were no significant differences between the subsample 
and the larger cohort for the measured variables presented in Table 1(p > 0.05). Adherence to treatment regimen 
was measured by parent reports and returned treatment capsule counts. Parent reports indicated adherence for 
the micronutrient group was 95.3% (+/−6.3), and 93.4% +/−7.6) for the placebo group. Capsule counts indi-
cated that adherence in the micronutrient group was 89.94% +/−17.2) and 91.0% +/−7.3) for the placebo group. 
The large standard deviation in the micronutrient group resulted from one participant and adherence calculated 
in the absence of this participant was 95.7% +/−3.4). Because this is a pilot study, and the concentration required 
for microbiome modification is unknown, this individual was not excluded from the analyses. The response rate 
in this study was consistent with that reported in the large cohort, with 50% responders (5/10) in the treatment 
group versus 29% (2/7) in the placebo group. However, there was no significant difference between ADHD-IV-RS 
and CGAS metrics in the two groups. Further information regarding participants and eligibility is available in 
Rucklidge et al.36. The diet intake questionnaire indicated that there was no significant difference in the recorded 
dietary habits between pre and post RCT for either group, with no significant group difference at post-RCT, after 
controlling for pre-RCT (F1,15 = 0.060, p = 0.81).
Sequence processing. Files were processed using the DADA2 package, after which there were 18,976,535 
sequences with 4,474 sequence variants from all samples. The mean sequence frequency per sample was 558,133 
and all samples had a read number greater than 285,765.
Classification of OTU. OTUs were classified using QIIME2 and the.biom file was imported into the R statis-
tical package, Phyloseq for further analysis (summarised in Table 2). For all sequence variants, bacteria accounted 
for 87% of assigned variants. The main phyla in all individuals was Bacteroidetes with a relative abundance of 
46.8% +/− 3.9). The three next most abundant phyla were Firmicutes (45.3%, +/− 2.2), Proteobacteria (0.04%, 
+/− 0.05) and Actinobacteria (0.03%, +/−0.02). For both the micronutrient and placebo groups the dominant 
phyla shifted from Firmicutes to Bacteroidetes between the pre- and post-RCT time points, where Firmicute 
abundance remained consistent. Although Actinobacteria only accounted for a small portion of the top phyla, 
there was a substantial decrease in abundance observed in the post-RCT, micronutrient group (Table 2). For the 
relative frequency of all bacteria detected at the phylum level see Supplementary Fig. 1 and 5, and for the relative 
frequency of all bacteria detected at the genus level see Supplementary Fig. 2. For further visualisation of the rel-
ative frequencies for the full dataset, Supplementary File 4 can be uploaded into the interactive visualisation tool 
available at https://view.qiime2.org/.
Control Treatment
n = 7 n = 10
Population variables (standard deviation)
Body mass index 16.6 (3) 19.39 (2.9)
Age 9.3 (1.3) 10.29 (1.9)
ADHD symptoms* 44.6 (4) 41.60 (11.3)
Table 1. Clinical description of population. *Based on clinician ratings using the ADHD-IV-RS.
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Alpha and beta diversity analysis. The within sample phylotype richness (alpha diversity) and dissimi-
larity (beta diversity) were calculated from the rarefied frequency table. The pairwise differences were then calcu-
lated by subtracting pre-RCT measures from the post-RCT for each individual. This enabled the comparison of 
changes at each stage (pre and post) and between each group (micronutrient and placebo). This was performed 
within the QIMME2 longitudinal plugin which is specifically optimised for analysis of paired samples. There 
was a significant difference in the change of observed OTUs between the treatment and placebo groups (Kruskal 
Wallis test p = 0.05, H = 3.8) (Fig. 2A). However, within each group (between baseline and post-RCT) there was 
no significant change (p > 0.2) (Fig. 2B). There was no significant quantitative change between the placebo and 
micronutrient treatments, as assessed using Shannon diversity index (Kruskal Wallis p > 0.1, H = 1.4), which 
is a quantitative measure of species diversity (Fig. 3A). However, the placebo group demonstrated a significant 
decrease in community richness between pre and post-RCT (Wilcoxon signed-rank test, adjp = 0.04) (Fig. 3B). 
There was no significant change in beta diversity between pre- and post-RCT, assessed using weighted and 
unweighted unifrac distance matrices (data not shown).
Differential abundance. We next investigated how the micronutrient treatment influenced the relative 
abundance of microbial features at each time point. We first used Analysis of Composition of Microbiomes 
(ANCOM)45 implemented through the QIIME2 ANCOM plugin in order to identify features that significantly 
differed in abundance from one or more of the four groups (micronutrient pre-RCT, micronutrient post-RCT, 
placebo pre-RCT and placebo post-RCT). The ANCOM algorithm determines significance by plotting calculated 
F-statistics on the x-axis and W-statistics on the y-axis. The F-statistics is a measure of the effect size difference 
for a particular species between the study groups, and the W-statistic is the strength of the ANCOM test for 
the tested number of species. In total 11 phyla were identified: Euryarchaeota, Actinobacteria, Bacteroidetes, 
Cyanobacteria, Firmicutes, Fusobacteria, Lentisphaerae, Proteobacteria, TM7, Tenericutes, and Verrucomicrobia; 
however, Actinobacteria were the only phylum to demonstrate a significant change in response to treatment 
(W = 6, clr f statistic = 7.5) (Fig. 4A). This observation was consistent for the taxonomic classification levels of 
class (data not shown) and order, and at the order level the effect was attributed to a decrease in the abundance 
of Bifidobacteriales (W = 3, clr f statistic = 6.04) (Fig. 4B). Marginally significant changes in differential abun-
dance were also observed for the orders Fusobacteriales (W = 2, clr f statistic = 2.1), Bacteroidales (W = 1, clr f 
statistic = 1.5), Pasteurellales (W = 1, clr f statistic = 1.3) and Burkholderiales (W = 1, clr f statistic = 1.4) (Fig. 4B). 
However, for these weaker observations, analysis of the raw data indicated that the effect was either not specific 
to the treatment, or that the statistical analysis was likely to be biased by low abundances of assigned sequence 
variants. Therefore, these observations were not further pursued in subsequent analyses.
Longitudinal analysis of relative frequency. Because ANCOM does not currently support pairwise 
analysis of samples within QIIME2, we further investigated the magnitude of changes by plotting the relative bac-
terial frequency for each individual using the q2-longitudinal plugin for pairwise differences. For this analysis, the 
relative frequency (as opposed to differential abundance) of assigned sequence variants were calculated from the 
DADA2 feature table (Supplementary File 5), and significance was assessed by comparing the pairwise difference 
between baseline and post-RCT samples for the micronutrient and placebo groups.
In the post-micronutrient treatment group, Actinobacteria frequency significantly decreased by approximately 
2% (adjp = 0.01). Although a decrease was also observed in the placebo group for several individuals, the pairwise 
difference did not reach significance (adjp = 0.06) (Fig. 5A). Proteobacteria demonstrated a minor, but significant 
increase in the micronutrient group, but not the placebo group (micronutrient adjp = 0.05, placebo adjp = 0.2);. 
However, the raw data had high inter-individual variability and was substantially influenced by a single outlier 
in the micronutrient group, which is likely to be why ANCOM did not attribute this effect to the micronutrient 
treatment (Fig. 5B). This effect was therefore not investigated at lower taxonomic levels. Bacteroidetes abundance 
significantly increased in both groups (micronutrient adjp = 0.018, placebo adjp = 0.018) (Fig. 5C), and Firmicute 
abundance significantly decreased in both groups (micronutrient adjp = 0.018, placebo adjp = 0.018) (Fig. 5D).
We further investigated Actinobacteria frequency by filtering the dataset to only contain Actinobacteria, and 
performed statistical analysis at each subsequent phylogenetic level. The relative frequency of Bifidobacteriales 
decreased by approximately 25% post micronutrient treatment (micronutrient adjp = 0.056, placebo adjp > 0.20) 
(Fig. 6A), and this decrease was compensated by an increase of Coriobacteriales (micronutrient adjp = 0.057, 
placebo adjp = 0.24), which was not previously observed using ANCOM (Fig. 6B). At the genus level, the decrease 
in Bifidobacteriales was attributed to Bifidobacterium (micronutrient adjp = 0.056, placebo adjp = 0.24) (Fig. 6C) 










Baseline micronutrient 11.36 0.34 13.72 0.54 1.02 0.06 0.98 0.08
Post micronutrient 16.65 0.41 12.74 0.22 1.86 0.10 0.28 0.02
Baseline placebo 7.16 0.29 9.13 0.22 0.66 0.05 0.67 0.04
Post placebo 11.41 0.41 9.90 0.42 1.24 0.10 0.60 0.02
Table 2. Relative frequency of each major phylum. *Summary of (non-rarefied) frequency table generated by 
QIIME2
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Although no significant change was observed at the family level for Coriobacteriaceae, at the species level the 
frequency of Collinsella aerofaciens significantly increased in the micronutrient group by approximately 20% 
(adjp = 0.01) with no mean change in the placebo group (adjp > 0.7) (Fig. 6D).
Prediction of functional profiles. Analysis performed using PICRUSt identified 328 KEGG Orthology 
pathways, and analysis performed using Tax4Fun identified 6196 KEGG Orthology pathways. We did not detect 
significant associations between change in pathway abundance and treatment, after adjustment for multiple test-
ing in either data set (adjp > 0.3 and 0.9) (data not shown).
Correlation between ADHD behaviours and relative abundance of Actinobacteria. We next 
performed a preliminary investigation into the correlation between bacterial abundances and ADHD clinical 
ratings (C-GAS for global functioning and ADHD-IV-RS for ADHD specific behaviours). This analysis was first 
performed on the baseline samples (pre-RCT) using relative frequencies from the Actinobacteria filtered fre-
quency table. At the phylum level there was a general trend that suggested increased Actinobacteria may be asso-
ciated with ADHD-IV-RS; however, this effect did not reach significance (Fig. 7A). When collapsed at the genus 
level we observed a significant correlation between a higher relative abundance of Bifidobacterium and a lower 
ADHD-IV-RS score (t = −2.3, df = 15, p = 0.04) (Fig. 7B), although it should be noted that three outliers are likely 
to have disproportionately contributed towards this effect. There was no significant correlation with C-GAS, or 
with the genus Collinsella (data not shown). We then further investigated this effect by separately visualising the 
pre and post-RCT data for the placebo (Fig. 7C) and the micronutrient group (Fig. 7D). Although no significant 
correlations were observed, the general trend suggested that post micronutrient treatment, a low abundance of 
Bifidobacterium was associated with a low ADHD-IV-RS score (Fig. 7D), which is contradictory to the general 
trend observed in the pre-RCT and placebo groups.
In an attempt to incorporate the longitudinal data we performed a pairwise repeated measures correlation, 
which looks at the change between pre and post-time points for each individual. This demonstrated that there 
was a significant pairwise correlation between a decreased ADHD-IV-RS score and decreased Actinobacteria 
Figure 2. Pairwise difference plots for Alpha and Beta diversity metrics. Treatment group is represented on the 
x-axis and pairwise change between pre and post measurements are demonstrated on the y-axis. The asterisk 
denotes significance (p = 0.05). (A) Pairwise difference comparison in observed OTUs (Alpha diversity). (B) 
Pairwise difference comparison of community richness using Shannon indices (Beta diversity).
Figure 3. Pairwise difference plots for Alpha and Beta diversity metrics. Treatment group is represented on the 
x-axis and pairwise change between pre and post measurements are demonstrated on the y-axis. The asterisk 
denotes significance (adjp = 0.05). (A) Pairwise difference comparison in observed OTUs (Alpha diversity). (B) 
Pairwise difference comparison of community richness using Shannon indices (Beta diversity).
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abundance between pre and post-RCT (p = 0.02, r = 0.55) (Fig. 7D), and when assessed against the C-GAS var-
iable (where the higher score is indicative of better functioning) there was also a significant pairwise correlation 
Figure 4. Differentially abundant microbial taxa identified by ANCOM. Volcano plot of differential abundance 
at the group level (pre-RCT placebo, pre-RCT micronutrient, post-RCT placebo and post-RCT micronutrient). 
F-statistics are represented on the x-axis and W-statistics on the y-axis. The F-statistics are a measure of the 
effect size difference for a particular species between the study groups, and the W-statistic is the strength 
of the ANCOM test for the tested number of species. (A) Differential abundance at the phyla level, the 
square represents Actinobacteria, the triangle represents Bacteroidetes, the diamonds represent Firmicutes, 
Proteobacteria, and Fusobacteria, circles represent Lentisphaerae, cyanobacteria, Verrucomicrobia, Tenericutes, 
Euryarchaeota and TM7. (B) Differential abundance at the order level, the square represents Bifidobacteriales, 
the triangle represents Fusobacteriales, diamonds represent Pasteurellales, Burkholderiales and Bacteroidales, 
and circles represent Cerasicoccales, YS2, Actinomycetales, Clostridiales, Victivallales, Verrucomicrobiales, 
Campylobacterales, Erysipelotrichales, Gemellales, RF32, Desulfovibrionales, Enterobacteriales, 
Lactobacillales, ML615J-28, Methanobacteriales, Anaeroplasmatales, Turicibacterales, RF39, Coriobacteriales, 
and Streptophyta.
Figure 5. Phyla level comparison in pairwise relative frequency at each treatment stage. The y-axis corresponds 
to relative frequency (as percentage), and treatment group is presented on the x-axis. The asterisk denotes a 
significant change (adjp ≤ 0.05) between pre and post-RCT groups. (A) Actinobacteria (B). Proteobacteria (C). 
Bacteroidetes (D). Firmicutes.
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(r = −0.49, p = 0.04) (Fig. 7D). Although a consistent general trend was observed at lower taxonomic lev-
els, including Bifidobacterium, this did not meet significance due to low statistical power (data not shown). 
Furthermore, the potential influence of the micronutrient treatment on this correlation is unclear as we did not 
have sufficient sample size to incorporate the treatment variable into this analysis. Power analysis was performed 
using the effect from our weakest correlation (C-GAS, r = −0.43), and suggested a sample size of ~200 would pro-
vide ~ 80% power to detect a significant effect with an adjusted p-value of 0.05 (adjusted for 5000 tests). However, 
it should be noted that performing an adjusted statistical model that accounts for treatment, age and BMI will 
further reduce statistical power.
Discussion
Our analysis investigated changes in the faecal microbiome composition during a 10-week double-blind RCT 
comparing micronutrient and placebo treatments. Our pilot study consisted of a subset of children diagnosed 
with ADHD, who had participated in a 10-week RCT comparing a broad spectrum micronutrient treatment with 
a placebo36. Investigating dietary effects on the microbiome is a growing area of research10, and our exploratory 
research is one of the first microbiome analyses associated with controlled nutrient manipulation in humans, per-
formed using an RCT11, and is the first to investigate such changes with respect to ADHD. For each individual, the 
microbiome was assessed using 16S rRNA gene sequencing on the Illumina MiSeq platform. These preliminary 
results suggest that micronutrient supplementation may be associated with small, subtle changes in human gut 
microbiome composition.
We did not detect any substantial change in alpha or beta diversity between the pre and post time-point meas-
ures in the micronutrient or placebo group. However, observed OTUs significantly increased in the treatment 
group, and the magnitude of the change was significantly larger than the placebo group, which showed no mean 
change. OTUs are a qualitative measure of community richness, and this result suggests that micronutrient treat-
ment may support a more diverse microbiome, or aid in protecting against random fluctuations. A similar change 
was observed with the Shannon diversity index, which is a quantitative measure of species diversity; however, the 
effect was not as pronounced. Metrics that incorporated phylogenetic relationships, such as the Faith’s Diversity 
measures did not significantly differ. Analysis of the raw data indicated that the changes in alpha diversity were 
largely driven by cumulative changes in low abundance species and this change was therefore not observed at the 
phyla level (Table 1), and was not detected using relative frequencies. This effect was not likely to have resulted 
from incorrect attribution of sequence variants, as we excluded features that were observed less than 100 times 
across samples, which is a higher threshold than is used in most microbiome studies.
We anticipated that the observed modifications in the human microbiome composition were likely to reflect 
responses to changing metabolic requirements in the micronutrient group. We therefore predicted functional 
KEGG Orthology pathways using two common bioinformatic algorithms (PICRUSt and Tax4Fun) that rely 
Figure 6. Relative frequency at each treatment stage. The y-axis corresponds to relative frequency of the 
investigated phylogenetic level (as percentage), and treatment group is presented on the x-axis. Relative 
frequency is calculated from the assigned sequence variants, filtered to contain only Actinobacteria, and 
collapsed at each phylogenetic level. The asterisk denotes a significant change (adjp ≤ 0.05) between pre and 
post-RCT groups. (A) Bifidobacteriales (B) Coriobacteriales (C) Bifidobacterium (genus) (D) Collinsella 
aerofaciens.
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on metagenomics computation, predicted from the 16S rRNA gene sequences. This approach did not detect a 
significant association between the micronutrient treatment and the abundance change in predicted functional 
pathways. This was at least partially due to the small sample size, which substantially reduced statistical power 
for detecting such changes. Furthermore, 16S rRNA gene sequencing is not an optimal approach for predicting 
functional changes, as it is based on the presence or absence of a single bacterial gene, from which metagenomics 
predictions are inferred53–55.
We next investigated differential abundances at each taxonomic level using the ANCOM package and also 
repeated the analysis using pairwise differences. The relative abundance of Actinobacteria significantly decreased 
in response to micronutrient administration, and this effect was significant at the taxonomic levels of class and 
order, where changes in Bifidobacteriales appeared to be driving the effect. These observations reinforce the 
findings from a similar study by Jaeggi et al.11. Bacteria from the genus Bifidobacterium demonstrated the largest 
Figure 7. Relative Bacterial Frequency and ADHD measures. The y-axis corresponds to relative bacterial 
frequency (%) and the ADHD measure is represented on the x-axis. (A) Actinobacteria (phylum) plotted 
against ADHD-IV-RS score for the baseline measurements. (B) Bifidobacterium (genus) plotted against ADHD-
IV-RS score for the baseline measurements. (C) Bifidobacterium (genus) plotted against ADHD-IV-RS score 
for the placebo group; black represents the baseline samples and grey represents the post-RCT samples. (D) 
Bifidobacterium (genus) plotted against ADHD-IV-RS score for the micronutrient group; black represents the 
baseline samples and grey represents the post-RCT samples. (E) Actinobacteria (phylum) plotted ADHD-
IV-RS score for the full dataset, post-RCT and pre-RCT data points from the same participant are connected 
by arrows, black represents the micronutrient group and grey represents the placebo group. (F) Actinobacteria 
(phylum) plotted C-GAS score for the full dataset,post-RCT and pre-RCT data points from the same participant 
are connected by arrows; black represents the micronutrient group and grey represents the placebo group.
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decrease in relative abundance, and although 16S rRNA analysis is not well suited to taxonomic classification at 
the species level, these tentative results suggested that B. longum and B. adolescentis were the two major species 
contributing towards this effect. This decrease in relative frequency was largely compensated by an approximately 
20% increase of the genus Collinsella, from the order Coriobacteriaceae, which were the only species that signif-
icantly increased in the micronutrient group. It should also be noted that at the species level, statistical power 
was reduced and the absence of these species from some individuals increased variability. Furthermore, pairwise 
difference analyses were performed on a dataset that was filtered only to contain Actinobacteria, and although 
this is a common technique, the adjustment for false discovery is less than when the analysis was performed on 
the full dataset (as with ANCOM).
There is growing evidence to support a role of diet in the regulation of ADHD behaviour, and although it is 
likely that the gut microbiome plays a significant role56–58, to date, there has been very limited scientific investiga-
tion into the biological connection. The primary objective of this pilot study was to investigate the potential influ-
ence of micronutrient administration on the gut microbiome. This sub-cohort consisted of paediatric patients 
with ADHD, and in order to predict an appropriate sample size for future studies we performed a preliminary 
investigation into the correlation between bacterial abundance and the reported ADHD metrics. Due to the small 
sample size we were unable to incorporate the micronutrient treatment variable into this analysis, although the 
dataset was filtered to contain only bacteria from the phyla Actinobacteria, as these demonstrated a significant 
change in response to the micronutrient treatment.
In our dataset we identified Bifidobacterium as being of potential relevance to ADHD; however, the out-
comes of our results are unclear and appeared contradictory. Overall there appeared to be a general trend sup-
porting the observation that higher Bifidobacterium correlated with a lower ADHD-IV-RS score, except for 
post-micronutrient treatment where a low Bifidobacterium abundance was associated with a low ADHD-IV-RS 
score. Although the treatment likely contributed towards this effect, we did not have sufficient power to incor-
porate this variable into the analysis, and potential outcomes are unknown. Pairwise repeated measures cor-
relation, which incorporates pre and post-RCT data, did not have the power to detect this effect, although a 
pairwise decrease in ADHD-IV-RS score was associated with a pairwise decrease in the relative abundance of 
Actinobacteria at the phyla level. These pilot data suggest a much larger study is warranted, and power analysis 
indicates a samples size of 200 individuals would be suitable. In the absence of such a large study, these current 
results should be interpreted with caution.
It is interesting to note that several recent investigations in this area have also identified the genus 
Bifidobacterium as having potential relevance to ADHD;28–30 and likewise the outcomes have also been con-
tradictory. Several studies have found Bifidobacterium including B. longum appeared to have a protective effect 
against developing neuropsychiatric disorders, including ADHD29,30, whereas Aarts et al.28 report a higher abun-
dance of Bifidobacterium in ADHD cases compared to controls. Potential causes for these contradictory results 
are discussed by Aarts et al.28, and heterogeneity in the diagnosis of neuropsychiatric disorders is likely to be 
an additional confounding factor in many studies. Furthermore, our analysis was a pilot-study and is therefore 
prone to bias from the small sample size where large effects in a small number of individuals in each group dis-
proportionately contributed towards the change. Our data also demonstrate the dynamic nature of both ADHD 
metrics and the microbiome, where regression to the mean could contribute towards contradictory results, and 
therefore, future studies should incorporate multiple longitudinal time points. Furthermore, the role that the gut 
microbiome plays in the development of such disorders is unlikely to be directly causative or the result of a single 
bacterial genus, but instead part of a complex combination of many genera, with both genetic and environmental 
factors. Although the diet intake questionnaire indicated that there was no significant difference in the recorded 
dietary habits between pre and post RCT for either group, we cannot eliminate the possibility that the observed 
changes were related to macronutrient intake23 (rather than micronutrient intake), as this is technically difficult 
to quantify and record.
These findings suggest that micronutrient treatment does not correspond with large scale changes in commu-
nity composition and structure of the human faecal microbiome content during a 10 week RCT; however, small 
non-specific changes involving many phyla are likely to have contributed towards a minor community level effect. 
Although there were no substantial changes at the community level, we did observe a very specific decrease in 
the abundance of bacteria from the phyla Actinobacteria, which was largely attributed to species from the genus 
Bifidobacterium. Further research is required to establish the role that Bifidobacterium contribute towards neu-
ropsychiatric disorders; however, these findings suggest that micronutrient administration could be used as a safe, 
therapeutic method to modulate Bifidobacterium abundance, where required.
Conclusion
We investigated changes in the composition and structure of the human faecal microbiome content during a 
10-week RCT for micronutrient treatment, in a sample of children with ADHD. We did not observe substantial 
changes in community structure. However, we did detect a significant decrease in the abundance of species from 
the genus Bifidobacterium, which supports previous findings11. Currently there are contradictory conclusions in 
the literature regarding the role that the microbiome plays in neuropsychiatric disorders, and it is interesting that 
many researchers are identifying Bifidobacterium species as key drivers. This preliminary research is suggestive 
of a mechanistic interaction between Actinobacteria abundance and ADHD, which could have potential impli-
cations for modulating and regulating ADHD behaviour. Our pilot study provides an initial observation into this 
area of research, and highlights an interesting avenue for further investigation in a larger cohort. Furthermore, 
these novel results validate the need for future research on the biological connection between ADHD, diet and 
the microbiome11.
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Data Availability
All results are available within the manuscript or in the supplementary file, and original scripts used for data 
analysis are available on request.
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